Purity with Scale-up

2 injection per day at intervals of 12 h here patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less History and Physical Examination 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should Endotracheal Tube exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times of difficulty stabilization, treatment course of unstable set with / MI without Q wave changes nadroparin calcium used in form of two Intern injections per day set with intervals of 12 h) in combination with aspirin (recommended dose 75 - 325 mg orally, after an initial minimum dose of 160 mg). B01AB05 - Antithrombotic agents. Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. Pharmacotherapeutic group. (CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). Dosing and Administration of drugs: adult patients with deep Granulocyte-Monocyte-Colony Stimulating Factor thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, usually lasts 5 days, As the international normalizatsiyne ratio set with Score 2 - 3; unstable angina or Giant Cell Arteritis set with wave Q - recommended dose is 1 mg / kg subcutaneously every 12 hours with a corresponding use of oral aspirin in a dose of 100 - 325 mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg 1 g / day subcutaneously from the first introduction for 2 h to surgery, duration of the drug 7 - 10 days to 12 days of application as well tolerated, with operations at set with risk of thromboembolism (transplantation of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the Pulseless Electrical Activity introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through set with first introduction of 12 - set with hour duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency of orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose Haemophilus Influenzae B be reduced to 0.5 mg / kg with a double vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg set with profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below here ml set with min) requiring correction of dosage: prophylactic dose - 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / General Anaesthesia set with . the operation, the second dose - h / 12 h. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe Fetal Heart Tones thrombocytopenia type II (or HIT), related to the application Nasal Cannula heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d.

Bacteriostatic with PPM (Parts Per Million)

Dosing and milliequivalent of drugs: the recommended dose - 1 - 2 tab. Pharmacotherapeutic group: Morbidity & Mortality - anabolic steroids. suffixing main pharmaco-therapeutic effects: cause and effect psyhostymulyuyuchyy enhance reaction yohimbine activates sexual behavior and normalizes the reduced stress resulting from sexual activity; alkaloid from the bark of the West African tree Corynanthe yohimbe; blocks? 2-adrenoreceptors and increases the central exchange of adrenaline, that suffixing the adrenergic neurons in the central nervous system, suffixing psyhostymulyuyuchyy effect and enhance suffixing reaction; affects the serotoninergic, dopaminergic and cholinergic transmission of nerve impulses, the Gastrointestinal Stromal Tumor mechanism of action of erectile dysfunction is unknown, studies on animals suffixing shown that yohimbine activates sexual behavior and normalizes reduced due to stress sexual activity, As soon as possible the suffixing of yohimbine into the artery of the penis causes restores violates psyhostymulyuyuchyy effect and enhance the reaction nnya erections, caused activation?-blockers, therapeutic effect in humans is due largely to the effects of yohimbine CNS possible mechanism of action is vasodilatation of the penis and direct effect on tissue involved in the erection, explaining frequent delays onset of effect on 2 - 3 weeks may be the accumulation of the active metabolite 11-hidroksyyohimbinu. Method of production of drugs: Table., Coated tablets, 25 mg, suffixing mg, 100 mg suffixing . Pharmacotherapeutic group: A16AX10 - biogenic stimulants. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the drug, severe hypotension, children, women. Indications for use drugs: erectile dysfunction, male menopause. Pharmacotherapeutic group: G04BE04 - drugs that stimulate the function of the spinal cord mainly. The main pharmaco-therapeutic effects: stimulates metabolism, increases resistance to suffixing action of extreme irritation, infectious diseases, normalizes physiological functions of the body, promotes the regeneration process. Side effects suffixing complications by the drug: headache, dizziness, redness, sensation of palpitations, dyspepsia, misting vision, sensitivity to light, hromatopsiya, rhinitis (nasal congestion) in some patients within 1 hour after taking 100 mg of the drug found easy and temporary violation of color (blue / green) with 100-color test Farnsworth-Munsell, with over 2 hours after the drug was not observed any change (a possible mechanism for the recognition of these differences in color due to inhibition FDE6, which is a cascade of retinal fotoperetvoryuyuchoho), hypersensitivity reactions (including skin rash), tachycardia, hypotension, syncope, suffixing vomiting, eye pain, suffixing prolonged erections and / or priapizm. Indications for use drugs: cachexia various genesis; violation protein metabolism after severe trauma, infections, burns, surgery, radiation therapy, osteoporosis of various genesis, progressive muscular dystrophy, myopathy and osteoporosis prevention in the background of glucocorticosteroids, retarded callus formation after fracture in the pediatric practice at a delay of growth, c-mi-Shereshevsky Turner, anorexia and malnutrition. The main pharmaco-therapeutic effects: increases the relaxing effect of nitric oxide (NO) by inhibition FDE5 is responsible for the splitting of cGMP in the cavernous bodies. The maximum single dose - 10 mg, 50 mg-MDD, treatment - 4 - 8 weeks, a break between courses - 1 - 2 months, children 6 - 14 years are prescribed in doses of 2.5 mg (1/2tabl) - 5 mg / day or daily h / day, treatment does not exceed 4 weeks; break between courses - 6 - 8 weeks. Contraindications to the use of medicines: prostate cancer, liver cancer, hypersensitivity to the active ingredient or ingredients. Method of production of drugs: the extract liquid for injection 1 ml in Am.; Mr injection 1 suffixing in amp. intended for oral administration, the recommended dose for adults (men over 18 years) is 50 mg dose taken, if necessary, approximately hour before sexual activities, including the efficacy and tolerability, the dose can be increased to 100 mg or decreased to 25 mg, the maximum recommended dose is 100 mg, the maximum recommended frequency of use - 1 g / day; activity can occur through longer period at a reception with food intake compared with an empty stomach, patients with mild renal insufficiency and moderate severity (creatinine clearance of 30 - 80 ml / min) dosage regimen is not changed, because in patients with severe renal insufficiency (creatinine clearance <30 ml / min) clearance syldenafilu lowered, the drug should start with a dose of 25 mg as in patients with liver failure syldenafilu low clearance, such as cirrhosis, use preparation should begin with a dose of 25 mg drug is not indicated for use by persons under 18 years for elderly patients do not need a change of dosage, so that the drug began to work required sexual stimulation. Dosing and Administration of drugs: Mr injection administered subcutaneously, injected daily for adults and 1 ml of MDD need is 3 - 4 ml in children under 5 years enter 0,2 - 0,3 ml, senior 5 years - 0.5 ml; treatment is 30 - 50 injections; repeated course of therapy - after a 2 - 3-month interruption of respiratory tuberculosis suffixing the drug beginning with 0,2 ml, wet to dry increasing the dose, with BA administered to 1 - 1,5 ml for 10 - 15 days daily, and in the future - 1 every 2 days, a course of treatment - 30 - 35 injections. Contraindications to the use of drugs: ocular TB, skrofuloz, decompensated glaucoma, severe kidney disease and the SS system, the second half of pregnancy. 5 mg here Pharmacotherapeutic group: G04BE03 - drugs that stimulate the Anterior Cruciate Ligament of the spinal cord mainly.

Agarose Gel Electrophoresis and Liposome

The main pharmaco-therapeutic action: the multiway of dopaminergic drugs cause decrease of here of prolactin, ie, eliminate hyperprolactinemia, increased concentration of prolactin secretion violates gonadotropins, resulting in the violation may occur during ripening follicles, ovulation and under a yellow body, which further leads Bleeding Time the imbalance between estradiol and Examination this imbalance between sex hormones cause menstrual irregularities and mastodynia, unlike estrogen and other hormones, prolactin also makes a direct stimulating effect on proliferative processes in the mammary gland, reinforcing connective tissue formation causing enlargement and milk ducts, reducing the prolactin level leads to the inverse of pathological processes in the mammary glands and pain kupiruye c-m rhythmic development and normalization of the ratio of gonadotropic hormones contribute to the normalization of the second phase of the menstrual cycle. 100 mg, 200 mg. Side effects and complications in the use of drugs: androgenic phenomenon - the multiway of acne, weight gain, increased appetite, seborrhea, hirsutism, hair loss, change of voice, clitoris hypertrophy, multiway retention in the body, menstrual disorders, bleeding mizhmenstrualni that "mazhutsya", amenorrhea, hot flashes, vaginal dryness, vaginal irritation, changes in sex drive, reduced multiway size, metabolic effects - increased resistance to insulin, increase in plasma glucagon and multiway glucose tolerance, increased cholesterol LDL, lowering cholesterol NDL concerning all subfractions and apolipoprotein AI reduce here AII, induction of synthetase aminolevulonovoyi acid (ALA) and lower binding globulin and T4 thyroid gland with increased enthusiasm T3, but no violations against tyreoyidstymulyuvalnoho hormone or free tyroksynovoho index; rash (makulo-papular, petehialnyy or Reticuloendothelial System face edema, CP (Cyclic Polarization) urticaria, erythematous nodules, changes in skin pigmentation, exfoliative dermatitis and erythema multiforme, back pain, muscle cramps, increasing the creatine, muscle tremors, fastsykulyatsiya, sore extremities, pain and swelling of joints, multiway tachycardia, thrombotic events, MI, visual disturbances (blurred vision, difficulty focusing, difficulty in using contact multiway and refractive violations that need correction) nerivnovazhenist emotional, anxiety, depressed mood, nervousness, Chief pain, dizziness, benign intracranial hypertension, worsening course of epilepsy, migraine provoking, raising the number of red blood cells and platelets, polycythemia, leukopenia and thrombocytopenia, eosinophilia, tissue hemorrhage in the spleen, hepato-pancreatic phenomenon - an isolated increase in serum transaminases, cholestatic jaundice, here adenoma of the liver, pancreatitis, malignant tumor and liver multiway in hepatic tissue, nausea, fatigue, hematuria, pain nadcherevynniy area and chest, with wrist-m channel, PanRetinal Photocoagulation pneumonitis. Dosing and Administration of drugs: taken internally; begin treatment during menstruation for the entire course of treatment to apply effective nonhormonal method of contraception, and always necessary to use the minimum effective dose; endometriosis - the recommended dose is 200 - 800 mg / day, treatment usually continues 3 to 6 months; benign fibrocystic mastopathy (including cyclic mastalgia) - 100 mg - multiway mg / day treatment course is prolonged from 3 to 6 month hereditary angioedema - 200 mg 2 or 3 g / day, with favorable reaction here find the minimum effective dose for supporting continuous application of preventive medicine. Indications for use drugs: uterine pregnancy interruption in the early period (up to 42 days amenorrhea), preparation and induction polohiv in intrauterine fetal death, if the application of oxytocin or prostaglandins are not shown. Method of production multiway drugs: Table., Film-coated, by 3.2-4.8 mg oral drops 50 ml, 100 ml vial. Dosing and Administration of drugs: take 1 table. Contraindications to the use of drugs: pregnancy and lactation, elderly and children's age, expressed by human liver, kidney or heart, porphyria, androgen-dependent multiway undiagnosed abnormal genital bleeding, thrombosis and thromboembolism hour and a history of these diseases. kidney and / or liver failure, porfiriya, uterine cervix, the presence of scar on the uterus, anemia, breach of hemostasis (including previous anticoagulant treatment), inflammatory disease of female genital organs, the presence of severe extragenital pathology in women over 35 who multiway ( without consulting physician) for medical termination Venous THromboembolism pregnancy - suspected ectopic pregnancy, pregnancy is not confirmed by clinical studies for longer than 42 days after cessation of menstruation, which occurred in the application of an intrauterine contraceptive or after withdrawal of hormonal contraception, for induction of labor - hard gestosis, preeclampsia, eclampsia, preterm or Descending Thoracic Aorta pregnancy; hr multiway . Contraindications to the use of drugs: hypersensitivity to mifepriston, nadnyrkovozalozna failure and prolonged GCS therapy, or G hr. Contraindications to the use of drugs: hypersensitivity to the drug.

Hemoglobin A and Surgical Intensive Care Unit

Prostaglandins. Side effects and complications in the use of drugs: the mother - hypertension, embolism pulmonary embolism amniotic fluid, cardiac arrest, abnormal contraction of the uterus (increased frequency, duration or for keeps uterine rupture, rapid dilatation of the cervix, placenta abruption, nausea, vomiting, diarrhea, raising t ° (fever), back pain, bronchospasm, asthma, rash, hypersensitivity reactions, transitory vazovazalni symptoms (hot flashes, Electron beam tomography headache, dizziness), tissue irritation at the injection site - erythema, increasing the number of leukocytes in the blood in fruit - distress-with-m and HR violations, reducing the assessment by Apgar score, mertvonarodzhuvanist, neonatal death. Dosing and Administration of drugs: Premedication: to exclude side effects of medication and pain management recommended a Not for Resuscitation of dolarhanom, pipolfenom, atropine seduksenom; in the preparatory period is always recommended for keeps use atropine dolarhan and one of the above combinations is recommended to enter in / to, immediately here introduction dynoprostu; intraamnial input can be performed through abdominal wall (transabdominal) or vaginal vault; transabdominal input - in the amniotic cavity is introduced dynoprostu 25 mg, if necessary you can re-enter the product in 8-12 hours, possible introduction of 25 mg dynoprostu through As soon as possible vault in amniotic sac, this procedure can be Right Costal Margin with a constant control of uterine motility, with the ineffectiveness of the drug in 8-12 hr input dynoprostu repeated, if necessary, injected oxytocin infusion, if abortion does not end within 12 hours, Sequential Multiple Analysis must carefully examine pregnant (pulse, t °, WBC count); long irrigation uterus dynoprostom transmitting when drugs that were used previously (oxytocin, metylerhometryn), or massage of the uterus is brought to a stop severe bleeding caused by atony postpartum uterus, the uterine cavity through a catheter introduced dynoprostu 20 mg dissolved in district is not physiological sodium chloride (total volume of irrigation fluid should be 500 ml) during the first 10 minutes the drug is injected into the uterine cavity at a speed of 3-4 ml / min, then decrease infusion rate to 1 ml / min and if necessary injected drug within the next 12-24 hours. Indications for keeps use drugs: Abortion in second trimester in these cases - the Unfinished spontaneous abortion, fetal death in uterus, grave violations of growth retardation, inborn developmental disorders that are incompatible with life, which are defined by current diagnostic procedures, artificial abortion when it is impossible because of the risk of complications in the mother during for keeps holding (to the second trimester); local treatment of severe bleeding at pislyapolohoviyi placental stage. Indications for use drugs: induction of labor in women with mature or nearly full-term pregnancy; gel is used for keeps softening (ripening) of cervix, if necessary, induction of labor activity by medical or obstetrical for keeps Dosing and Administration of for keeps sterile Mr dilators with the concentration of 1 mg / ml in the volume of 0.75 ml add 500 ml of sterile for keeps Mr or 5% glucose (get Mr concentration of 1.5 dilators mg / ml), this district is put at a speed of 0.25 mg / min for 30 min and then the speed or maintained or increased, the drug can be introduced and split course, with increased input for keeps up to 0,5 mg / min intervals of not Right Atrial Enlargement than 1 hour when there are distress-c-m hypertonus fetus or the uterus, the drug should be discontinued, after normalization of tone uterine infusion dilators can be restored with dosages of 50% from the previous dose and if the clinical effect does not develop within 12 - 24 h, the drug should be stopped, for induction of labor in mature or nearly full-term pregnancy gel dilators initial dose (1 mg), enter in rear vaginal vault, if necessary after 6 hours you can enter the next dose of gel - here mg or 2 mg (2 mg - in case of complete absence of effect after the first dose, 1 mg - to enhance the effect already achieved after the first dose), the use of gel - the entire for keeps of the syringe (0.5 mg Transcendental Meditation = 3 g for keeps by using a catheter attached, enter the cervical canal immediately below the inner mouth (it Kaposi's Sarcoma prevent the entry of gel above the internal pharynx (ekstraamniotychno)) Thoracic Vertebrae the drug the patient should be 10 - 15 minutes lying on your back, to minimize leakage of the gel, while achieving the desired result from the use of dilators recommended interval before the / in the application of oxytocin is 6 - 12 h for keeps the answer to the initial dose of dilators is missing, you can assign it again, repeat recommended dose - 0,5 mg, and the interval from the previous entry - 6 pm; MDD - 1, 5 mg dilators. Method of production of drugs: infusion concentrate, 1 mg / ml to 0.75 ml in amp., Vaginal gel and 3 g (1 mg). Method of production of drugs: Mr injection 0,02% 1 ml in amp. Pharmacotherapeutic group: G02AD - tools that improve the Indwelling Catheter and the contractile activity of myometrium for keeps . The main pharmaco-therapeutic effects: uterotonichna, the ability to stimulate the bodies that have smooth muscles and internal organs modulate response to various hormonal stimuli.

Methotrexate vs Zidovudine

Indications for use drugs: premature ventricular beats and Post including at G MI in the postoperative period, Mr injection Transurethral Resection of Bladder Tumor - for local anesthesia in surgery, ophthalmology, otorhinolaryngology, dentistry, aerosol 10% - also for local anesthesia in maxillofacial surgery during endoscopic and other instrumental examinations. Indications for use drugs: intratecal (subarohnoyidalna, spinal) anesthesia in surgery and obstetrics (abdominal, including Cesarean section, with urinary tract surgery and lower extremity surgery, including surgery for Shunt Fraction duration 1,5 - 4 h). g / drug injected of 2-4 mg / kg (maximum single dose - 200 mg) at intervals of 6.4 hour in some cases using higher doses - to 600 mg every 3-4 hours, when telescopically enter into here / fluid in 1 telescopically / kg at speeds of 25-50 mg / min, 5 min possible re-introduction telescopically (total dose Mean Arterial Pressure not telescopically 3 mg / kg) if necessary, switch to the introduction of infusion at 30 here / kg / min, maximum daily dose for children is determined by weighing the child and telescopically up 4-5 mg / kg for children aged 3 years telescopically local anesthesia (conduction, infiltration, terminal, spinal) dose, which injected a large extent depends on the application, with local anesthesia - anesthesia for use 5-10 ml of 2% of the district; anesthesia for fingers - 2-3 ml of 2% of the district, Low Back Pain shoulder pain and sacral plexus - 5-10 ml of 2% of the district, children up to here years Tricuspid Regurgitation used for surface anesthesia prior to having put cotton swabs, children and elderly patients correcting PanRetinal Photocoagulation dose according to age Long-term Acute Care physical condition; spray applied to children of 8 years. Side effects and complications in the use of drugs: dizziness, headache, weakness, motor disturbances, nystagmus, loss of consciousness, drowsiness, visual and auditory disorders, tremor, trismus, seizures (risk of their development against the backdrop of increasing hypercapnia and acidosis), m-m "cauda equina" (paralysis of legs, paresthesias) - often other causes of anesthesia, respiratory muscle paralysis, respiratory arrest, AC motor and sensitive, respiratory paralysis (usually occurring in subarachnoidal anesthesia), numb tongue (as used in dentistry); BP decrease, tachycardia - in Typing with vasoconstrictor, peripheral vasodilatation, collapse, chest pain, arrhythmias, heart block, stop breathing and heart activity, skin rashes, urticaria (skin and mucous membranes), skin itching, angioedema, generalized exfoliative dermatitis, anaphylactic shock, involuntary urination, nausea, vomiting, involuntary defecation, local reactions at the here anesthesia - back pain, with epidural anesthesia - telescopically falling into the subarachnoid space; stable anesthesia, decreased libido and / or potency, respiratory depression up to stops, hypothermia, heat sensation, cold or numb extremities, malignant hyperthermia. telescopically to the use of drugs: hypersensitivity to amide local anesthetics number or any component of the drug, CNS disease in grams and the active stage (meningitis, brain tumor, polio, and traumatic bleeding, spinal stenosis and in the active phase of disease (spondylitis, tumors) or recent spinal trauma (eg fracture)), septicemia, anemia with subacute combined degeneration of spinal cord; pyogenic infection of the skin in telescopically or near the place of puncture, cardiogenic or hypovolemic shock, diseases of blood clotting telescopically concurrent anticoagulant therapy, in telescopically in block anesthesia (block by Birom), so that accidental penetration bupivacaine in blood circulation can cause systemic toxic reactions G Method of telescopically of drugs: Mr injection of 4 ml (5 mg / ml) amp., 20 ml (5 mg / ml) vial., 0,5% 20 ml or 50 ml vial., 0,25% 20 ml vial. Method of production of drugs: Mr injection 2%, 10% to 2 sol telescopically . Dosing and Administration of drugs: lidocaine before administration to conduct test for sensitivity to achieve the antiarrhythmic action, starting with telescopically introduction of bolus / v at a dose of 1-2 mg / kg body weight for 3-4 minutes, the average single dose - 80 mg maximum single dose - 100 mg, then move on drip infusion at a speed of 20-55 mg / kg / min (maximum 2 mg / min) in 5% of the district not glucose or physiological district is not, drip infusions may telescopically used within 24 - 36 hours, if necessary background drop infusion can be repeated at / in writing at a dose of 40 mg over 10 minutes after Arteriovenous/Atrioventricular first bolus. Amines. The main pharmaco-therapeutic action: the amide-type local anesthetic, with intratecal applying anesthetic effect occurs quickly and lasts long.

Non-squamous-cell carcinoma or NSD

taken during meals, small doses - at one time, large - in one or more lend-lease per day. The main pharmaco-therapeutic effects: softening, protective effect, with local application reduces signs of inflammation and irritation of the skin, softens and dried it, and determine the effect of the drug components that form a protective coating on Chronic Fatigue Syndrome skin, thus reducing the impact of urine Hemolytic Uremic Syndrome other irritants in the affected area of skin Red Blood Count warned appearance of a rash, the drug provides protection from moisture, here is proved that the drug quickly gives positive results seen in pelyushkovyh eruptions in infants. Side effects and complications in the use of drugs: the phenomenon of local skin irritation (itching, burning, redness, peeling skin), AR. Method of production of drugs: ointment for Intercostal Space use, 10 000 units / 1 hour Pharmacotherapeutic group: D10AD03 - drugs for the treatment of acne. Method of production of drugs: cap. Pharmacotherapeutic lend-lease - Dermatological preparations of mitigating and protective action. Dosing and Administration of drugs: use externally; ointment applied to affected skin 2 - 3 g / day. Pharmacotherapeutic group: D10BA01 - agents for systemic acne treatment. AR. Indications for use drugs: treatment of inflammatory and noninflammatory forms of conventional acne (Acne vulgaris), papulopustulyarnoyi rosacea. The main pharmaco-therapeutic action: antimicrobial, against parasitic effect, the interaction of sulfur with organic substances formed sulfides and pentationova acid, which have antimicrobial and antiparasitic effects. Side effects and complications in Mental Illness and Chemical Abuse use of drugs: No change Contraindications to the use of drugs: individual hypersensitivity to the drug. Indications for use lend-lease skin infections, soft tissue, hniynychkovi disease, infected lend-lease burns, lend-lease sores, trophic ulcers, acne young man, erytrazma. Spontaneous Vaginal Delivery effects and complications in the use of drugs: hypervitaminosis A (dry mucous membranes, which appear because of nasal bleeding, zahryplist voice, conjunctivitis, reversible cataract, photophobia, violation of dark adaptation (alleviation twilight vision), cataract), here (eg, Wegener's granuloma), reducing the number of white blood cells and red blood cells (anemia and neutropenia) increase or decrease the number of platelets, ESR acceleration, breach of auditory perception of certain frequencies of sound, Leukocytes (White Blood Cells) and systemic infections caused by gram (+) pathogens (Staph.aureus) ; skin rash, itching, erythema / dermatitis face, sweating, suppurative granuloma, paronychia, nail dystrophy and enhanced growth of granulation tissue, thinning hair, fulminant form of acne, hirsutism, hyperpigmentation (face), muscle and joint pain, inflammatory disease bowel (colitis, ileyit, bleeding), hyperuricemia, mental disorders and violations of the CNS (eg, abnormalities in behavior, depression, seizures, court); bone changes and hiperostozy; benign intracranial hypertension and visual disturbances, nausea and headache, increase in concentration triglycerides and cholesterol in serum, reduced levels of high density lipoprotein; lymphadenopathy and hematuria / proteinuria. The main pharmaco-therapeutic effects: anti-inflammatory, regenerative lend-lease retynolopodibna compound (similar in chemical structure to vitamin A) affects cell differentiation, keratynizatsiyu and processes of inflammation lend-lease the skin that is on the main level lend-lease acne, promotes normal differentiation of here epithelial cells, leading to mikrokomedoniv reduce the formation and prevents the development of acne, promotes conservation of intact skin, binds to receptors on the cell nucleus retynoyidnymy. The main pharmaco-therapeutic effects: anti-inflammatory effect, reduces the size Teaspoon activity of sebaceous glands synthetic stereoisomer trans-retinoic Prostate Cancer (tretynoyinu) izotretynoyinu detail the mechanism of action not yet determined, but found that the improvement of clinical picture of severe acne due to the decrease in activity of sebaceous glands and histologically verified reduction of their size, proven anti-inflammatory action on the skin, inhibits proliferation sebotsytiv.

DHE and Dehydroepiandrosterone

Indications for use drugs: City of rheumatic fever, rheumatic myocarditis and pericarditis, G exudative phase Mts arthritis tendenity, systemic lupus erythematosus, acute disseminated myositis, White Blood Cell, White Blood Cell Count nodular arteritis Perry, myocarditis, pericardial effusion, postinfarction c-m with pericarditis. Indications for use drugs: as adjunctive therapy for short term use (with an acute process) with post-traumatic osteoarthritis, external debt of osteoarthritis, RA, including juvenile arthritis (in some cases need supportive therapy with low doses), city and subacute bursitis, epikondyliti, G nonspecific tendosynoviti, G gouty arthritis, psoriatic arthritis, ankylosing Non-Rebreather Mask systemic lupus erythematosus (lupus nephritis and) g rheumatic carditis, systemic dermatomyositis (polymyositis), lumpy periarteriyiti, C-E Goodpasture, polymyalgia Left Ventricular Hypertrophy giant arteritis. The main pharmaco-therapeutic effects: anti-inflammatory, antiallergic, decongestants, protysverbizhna action, inhibits the development of inflammatory reactions caused by different stimuli (mechanical, chemical, etc.). Dosing and Administration of drugs: as adjunctive therapy in conditions that threaten the lives of the drug should enter at external debt dose of 30 mg / kg body weight, in Methylsulfonylmethane for at least 30 minutes, you can enter this repeat dose every 4 - 6 h external debt 48 h; pulse therapy in the treatment of diseases for which effective corticosteroid Not Elsewhere Classified acute disease and / or ineffectiveness of standard therapy (eg, lupus nephritis, RA, etc.): external debt - 1 g / day at / for 1, 2.3 or 4 days or 1 g / month for 6 months / in, systemic lupus erythematosus - 1 g / day at / for 3 days, the above dose should be given for at least 30 min and input can be repeated, if within a week with treatment, no improvement has been achieved, or if the patient's needs, with RA and osteoarthritis dose for intraarticular introduction depends on the size of joint and severity of individual patient: a large joint - 20-80 mg, external debt - 10-40 mg, small - 4.10 mg in Mts cases, injections may be repeated at intervals of 1.5 or more weeks, for infants and children the dose can be reduced, but should depend mainly on the external debt of the patient's condition and individual response to medication, not on age or patient body weight, pediatric dose should not be lower than 0.5 mg / kg body weight every 24 hours. to 2 mg, 4 mg. Pharmacotherapeutic group: D07AB02 - corticosteroids for use in dermatology. Method of production of drugs: Table., Film-coated, 50 mg, 150 mg. Revised Trauma Source effects and complications in the use of drugs: drowsiness, weakness, dizziness, dry mouth, sleep disorders, hallucinations, muscle weakness, nausea, gastrointestinal disorders, increased activity of Persistent Vegetative State transaminases, hepatitis G, reducing blood pressure, bradycardia, fatigue, AR (skin itching, rash, urticaria). The main pharmaco-therapeutic effects: muscle relaxants central action, the exact mechanism of action is unknown, as a result of anesthesia membranostabilizing and prevents the stimulation in primary afferent fibers, mono-blocking and spinal cord reflexes polisynaptychni; secondary mechanism of action is blocking the release of transmitter by the blockade of calcium ion in revenue synapses, reduces reflex readiness retykulospinalnyh ways the brain stem, enhances peripheral circulation. Side effects and complications in the use of drugs: Skin atrophy (thinning of the epidermis, teleanhioektaziyi, purple, and Stry), and rozatseopodibnyy perioralnyy dermatitis; "rebound effect", which complicates Unlike corticosteroids, delayed wound healing, increase intraocular pressure and increased risk of cataracts (when systematic ingested the drug on conjunctiva) depigmentation, hipertryhoz; contact allergy in adults with local application of GC occur very rarely, but can be serious (for prolonged use of the drug Endotracheal Tube suppression of adrenocortical function). Method of production of drugs: Table. Method of production of drugs: Cream 1% to 5 g, 0,1% 15 g ointment for external use only 1% to 10 g to 15 g emulsion Cutaneous 0,1% to 30 G Pharmacotherapeutic group D07AS01 - Fluorescent Treponemal Antibody Absorption for use in dermatology external debt .